Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (vol 123, pg 26, 2020)

被引：0
|
作者：
Gelsomino, Francesco [1 ]
Tiseo, Marcello [1 ]
Barbieri, Fausto [1 ]
Riccardi, Ferdinando [1 ]
Cavanna, Luigi [1 ]
Frassoldati, Antonio [1 ]
Delmonte, Angelo [1 ]
Longo, Lucia [1 ]
Dazzi, Claudio [1 ]
Cinieri, Saverio [1 ]
Colantonio, Ida [1 ]
Sperandi, Francesca [1 ]
Lamberti, Giuseppe [1 ]
Brocchi, Stefano [1 ]
Tofani, Lorenzo [1 ]
Boni, Luca [1 ]
Ardizzoni, Andrea [1 ]
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy
来源：
BRITISH JOURNAL OF CANCER | 2021年 / 125卷 / 02期
关键词：
D O I：
10.1038/s41416-021-01439-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：306 / 306
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Francesco Gelsomino
    Marcello Tiseo
    Fausto Barbieri
    Ferdinando Riccardi
    Luigi Cavanna
    Antonio Frassoldati
    Angelo Delmonte
    Lucia Longo
    Claudio Dazzi
    Saverio Cinieri
    Ida Colantonio
    Francesca Sperandi
    Giuseppe Lamberti
    Stefano Brocchi
    Lorenzo Tofani
    Luca Boni
    Andrea Ardizzoni
    British Journal of Cancer, 2020, 123 : 26 - 32
  • [2] Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Gelsomino, Francesco
    Tiseo, Marcello
    Barbieri, Fausto
    Riccardi, Ferdinando
    Cavanna, Luigi
    Frassoldati, Antonio
    Delmonte, Angelo
    Longo, Lucia
    Dazzi, Claudio
    Cinieri, Saverio
    Colantonio, Ida
    Sperandi, Francesca
    Lamberti, Giuseppe
    Brocchi, Stefano
    Tofani, Lorenzo
    Boni, Luca
    Ardizzoni, Andrea
    BRITISH JOURNAL OF CANCER, 2020, 123 (01) : 26 - 32
  • [3] Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
    Francesco Gelsomino
    Marcello Tiseo
    Fausto Barbieri
    Ferdinando Riccardi
    Luigi Cavanna
    Antonio Frassoldati
    Angelo Delmonte
    Lucia Longo
    Claudio Dazzi
    Saverio Cinieri
    Ida Colantonio
    Francesca Sperandi
    Giuseppe Lamberti
    Stefano Brocchi
    Lorenzo Tofani
    Luca Boni
    Andrea Ardizzoni
    British Journal of Cancer, 2021, 125 : 306 - 306
  • [4] Phase II study of NAB-paclitaxel in sensitive and refractory relapsed SCLC (NABSTER TRIAL)
    Gelsomino, F.
    Tiseo, M.
    Barbieri, F.
    Riccardi, F.
    Cavanna, L.
    Frassoldati, A.
    Delmonte, A.
    Longo, L.
    Dazzi, C.
    Cinieri, S.
    Colantonio, I.
    Tognetto, M.
    Baldari, D.
    Tofani, L.
    Ardizzoni, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase II Study of Combination of Nab-Paclitaxel and Gemcitabine for Relapsed Small Cell Lung Cancer (SCLC)
    Furqan, M.
    Zhang, J.
    Clamon, G.
    Abu-Hejleh, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S791 - S791
  • [6] Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
    Byrne, Margaret M.
    Sutamtewagul, Grerk
    Zeitler, William
    Mott, Sarah L.
    Zamba, Gideon K. D.
    Kojadinovic, Arsenije
    Zhang, Jun
    Abu-Hejleh, Taher
    Clamon, Gerald
    Furqan, Muhammad
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [7] Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer (SCLC)
    Pietanza, M. C.
    Sima, C. S.
    Polley, M. R.
    Sumner, D. K.
    Travis, V.
    Heguy, A.
    Ginsberg, M. S.
    Holodny, A.
    Kris, M. G.
    Krug, L. M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S507 - S507
  • [8] Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer
    Matsui, Yohei
    Yamada, Tadaaki
    Morimoto, Kenji
    Katayama, Yuki
    Hiranuma, Osamu
    Shiotsu, Shinsuke
    Tamiya, Nobuyo
    Takeda, Takayuki
    Morimoto, Yoshie
    Iwasaku, Masahiro
    Tokuda, Shinsaku
    Takayama, Koichi
    ANTICANCER RESEARCH, 2022, 42 (10) : 4921 - 4928
  • [9] A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC).
    Gandhi, Leena
    Heist, Rebecca Suk
    Lucca, Joan Vern
    Temel, Jennifer S.
    Fidias, Panos
    Morse, Linda K.
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
    Wan, Rui
    Guo, Yanrong
    Hao, Xuezhi
    Wang, Zhijie
    Duan, Jianchun
    Wang, Jie
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345